Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

APOE ϵ4 Allele Is Associated with Elevated Levels of CSF VILIP-1 in Preclinical Alzheimer’s Disease

Authors Wang L, Zhang M, Wang Q, Jiang X, Li K, Liu J

Received 21 October 2019

Accepted for publication 21 March 2020

Published 8 April 2020 Volume 2020:16 Pages 923—931


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jun Chen

Lijun Wang,1 Miao Zhang,2 Qian Wang,3 Xianguo Jiang,4 Kunyi Li,5 Jun Liu1 On Behalf of the Alzheimer’s Disease Neuroimaging Initiative

1Department of Neurology, Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Department of Medicine, Mount Sinai St Luke’s and West Hospital, New York, NY, USA; 4Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 5Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, Chongqing, People’s Republic of China

Correspondence: Jun Liu Email [email protected]

Objectives: Cerebrospinal fluid (CSF) visinin-like protein 1 (VILIP-1) has been suggested as a biomarker for neuron injury, which has been shown to have a important diagnostic value in symptomatic Alzheimer’s disease (AD). The study purpose is investigating potential effects of apolipoprotein E (APOE) ϵ4 on CSF VILIP-1 levels among the preclinical AD.
Methods: A total of 110 subjects (including 43 APOE ϵ4 carriers and 67 ϵ4 non-carriers) were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the present study.
Results: The results showed that VILIP-1 concentrations in the CSF were statistically significantly increased in APOE ϵ4 carriers in comparison with non-carriers. Increased CSF VILIP-1 level was positively associated with the concentrations of both CSF-tau and P-tau levels.
Conclusions: Our findings suggested that APOE ϵ4 might affect CSF VILIP-1 level in preclinical AD, indicating an important role of APOE ϵ4 in neuron injury leading to AD.

Keywords: APOE ϵ4, VILIP-1, Alzheimer’s disease, cerebrospinal fluid

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]